about
A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activityRapid screening for entry inhibitors of highly pathogenic viruses under low-level biocontainmentFatal measles virus infection prevented by brain-penetrant fusion inhibitors.Mechanism of measles virus-induced suppression of inflammatory immune responses.Interplay between virus-specific effector response and Foxp3 regulatory T cells in measles virus immunopathogenesisHuman herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9.Measles virus infection induces terminal differentiation of human thymic epithelial cells.Lethal Nipah virus infection induces rapid overexpression of CXCL10.Evaluation of adenovirus vectors containing serotype 35 fibers for vaccinationHenipavirus infections: lessons from animal models.The V protein of Tioman virus is incapable of blocking type I interferon signaling in human cells.Recent developments in animal models for human herpesvirus 6A and 6BPrevention of measles virus infection by intranasal delivery of fusion inhibitor peptidesMeasles fusion machinery is dysregulated in neuropathogenic variants.Nipah virus uses leukocytes for efficient dissemination within a host.Expression of CD150 in tumors of the central nervous system: identification of a novel isoform.Heparan sulfate-dependent enhancement of henipavirus infection.Experimental infection of squirrel monkeys with nipah virus.Nonstructural Nipah virus C protein regulates both the early host proinflammatory response and viral virulence.Immunosuppression caused by measles virus: role of viral proteins.Mechanism for active membrane fusion triggering by morbillivirus attachment protein.Wild type measles virus attenuation independent of type I IFN.HSP90 Chaperoning in Addition to Phosphoprotein Required for Folding but Not for Supporting Enzymatic Activities of Measles and Nipah Virus L Polymerases.Current animal models: transgenic animal models for the study of measles pathogenesis.Measles virus hemagglutinin triggers intracellular signaling in CD150-expressing dendritic cells and inhibits immune response.In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides.Henipavirus pathogenesis and antiviral approaches.Measles virus infection of human keratinocytes: Possible link between measles and atopic dermatitis.Suppression of Smad-1 mRNA expression level by Smad-2 likely control dichotomy of NF-κB and Smads mediated activation.Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.The role of contrasuppressor T cells in the adoptive transfer of contact sensitivity responses to picryl chloride.PolyI:C plus IL-2 or IL-12 induce IFN-gamma production by human NK cells via autocrine IFN-beta.Transgenic mice expressing human measles virus (MV) receptor CD46 provide cells exhibiting different permissivities to MV infections.[Endogenous retroviral sequences in the human genome can play a physiological or pathological role].Immunomodulatory properties of morbillivirus nucleoproteins.Understanding the interaction between henipaviruses and their natural host, fruit bats: Paving the way toward control of highly lethal infection in humans.High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.Animal models for human herpesvirus 6 infection.Contrasuppression and tumor rejection.
P50
Q28729918-DA7D7C14-2942-420C-926D-DAD29BF8D9A2Q28731583-51802E1F-C0BD-4DA5-91E1-C549BE677B07Q30557599-C87B0BAC-46A2-4E99-9811-9E109F6820C7Q31859037-BB3F63A5-725F-42CD-A36B-A360F66DD33EQ33421714-300E657A-48C2-42C3-AF0B-4E06CFB8AAECQ33602699-D31C6452-660F-4E4C-970A-3B01796392A1Q33653384-BC399E16-D2D7-433B-8963-9FBB82286A66Q34185782-12470188-3A0C-4FBD-A2F7-F85BE188CE22Q34507185-B997813C-F77E-4C05-A4BA-566E5ABCABDDQ34533606-3ADFE570-7610-47A5-BD3C-1DB9CF5A1F25Q34558886-3F94D52C-C06C-432D-B9A3-AD5FE8C7B4A0Q34717973-85C46C25-9703-4994-A17D-34B9ED311D51Q34991022-C24CE2B4-1F31-46C9-9155-DCEF28AC9597Q35111156-1F9DF505-2A6D-4448-AFAB-5C4A6B796EA6Q35140337-FB5751AA-3E40-4124-B332-997DFE6A02CCQ35566887-4F9CD1B3-C42D-4432-8DEC-DC027F9C04A8Q35677600-AA545812-2E0B-401B-989D-217C837275A9Q35877423-5A79D0F4-A686-4C7C-BDE7-4C91658564D6Q36276572-26DF1E8D-E8C0-42B2-A191-FC3C92A3029EQ36291876-1013EE0D-BD72-42DD-90D9-C3235347322AQ36506813-B3465C63-A4F5-491E-A53E-202B893783A8Q36509497-5BBF5113-268A-4CEE-B2BF-0A8751C8B44BQ37093466-593F50C5-C598-4ED4-81F7-F498EBF70F09Q37388567-A694C317-A0B0-487B-8D1E-3AFD69896320Q37402444-0877AB3A-B97C-4665-951E-DAC2E91EA661Q37512939-D18C7245-374F-44B2-B904-7C1D2DE90D05Q37715076-EB333E56-2914-412D-AD5A-F9F57FDC93F1Q38337204-5466DD80-6803-49EF-BAAB-E10E5786DDDCQ38715080-49A91B23-B05A-418F-82CC-4C2F2AC1B990Q38952773-98806D92-9D9F-4CBC-AF7F-3EBB9F158839Q39240212-B72A7C47-E9FD-4AE3-A734-988F4ABE276FQ39467939-5A842F1C-D696-49B0-9199-AD6CC4551194Q39804029-B7652FAD-ABCA-42C8-A101-5FBDAE77908CQ39876381-68636B6C-2B30-4F1E-A804-B16B43C141B0Q40204275-BD976D44-2D49-4A09-8250-DF9B0422B278Q40260067-AD53FE10-BE69-4EF5-A243-D2E3C6DE9ADCQ40382705-2D438210-50DC-4EB9-9A16-7E6DEFF40F51Q41498081-9BD2E1BE-3EBC-49A1-9A9E-67C7D9E95A4AQ41845061-A85B077A-4F62-4A34-9057-618AF50EC778Q42099820-91C19D5D-FCF2-42F8-A25E-5130195BCDF6
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Branka Horvat
@ast
Branka Horvat
@en
Branka Horvat
@es
Branka Horvat
@nl
Branka Horvat
@sl
type
label
Branka Horvat
@ast
Branka Horvat
@en
Branka Horvat
@es
Branka Horvat
@nl
Branka Horvat
@sl
prefLabel
Branka Horvat
@ast
Branka Horvat
@en
Branka Horvat
@es
Branka Horvat
@nl
Branka Horvat
@sl
P1053
M-3504-2014
P106
P21
P2798
P31
P3829
P496
0000-0003-0578-7765